Replies to post #269473 on Anavex Life Sciences Corp (AVXL)

[tredenwater2]

Great point Xena and this is what I am pulling for! Including the OLE data and PDD results to further support their MOA discussing PA and at the very least SAS specifically for PD(D) . PDD may already be in the current SAS wheelhouse for Alzheimers, IMO.

Getting close and trying to temper expectations. Amazing how long of a journey it has been. I feel like a minor degree in drug development could be added to my resume, lol. Just joshin but definitely learned alot from many o smart posters here!

Tred

[BIOChecker4]

Pure baseless speculation.

During the quarter 3 earnings call, Missing said, We will report exactly when we have the data.”

https://seekingalpha.com/article/4366822-anavex-life-sciences-corp-avxl-ceo-dr-christopher-missling-on-q3-2020-results-earnings-call?part=single

Since has never updated that statement, one must operate on the assumption that the guidance has not changed. And by the way, he has never acknowledged nor explained the delays in reporting the top-line PDD data, including why the data were not reported by the end of 2019 as he said he expected in the video interview from the BIO CEO conference.

The 2019 miss on the PDD top-line data, as well as the mid-year miss, cannot be explained away by more recent events.

[frrol]

They would not "hold off".

The company will release the results when they have them. There are no super secret meetings and delays of wonderfulness.

[blu_1]

Trial ended officially when, 9/30? That's what clinicaltrials.gov says, updated 9/2. So then gotta allow couple mos for analysis.